Excalibur Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.93M | Buy |
13,479
+30
| +0.2% | +$6.66K | 1.05% | 25 |
|
|
2025
Q4 | $3.07M | Sell |
13,449
-276
| -2% | -$62.9K | 1.11% | 23 |
|
|
2025
Q3 | $3.18M | Buy |
13,725
+24
| +0.2% | +$4.89K | 1.15% | 20 |
|
|
2025
Q2 | $2.54M | Sell |
13,701
-35
| -0.3% | -$6.5K | 0.95% | 25 |
|
|
2025
Q1 | $2.88M | Sell |
13,736
-19
| -0.1% | -$3.69K | 1.13% | 19 |
|
|
2024
Q4 | $2.44M | Sell |
13,755
-97
| -0.7% | -$17.8K | 0.97% | 25 |
|
|
2024
Q3 | $2.74M | Sell |
13,852
-205
| -1% | -$38.3K | 1.04% | 19 |
|
|
2024
Q2 | $2.41M | Buy |
14,057
+155
| +1% | +$25.7K | 0.98% | 23 |
|
|
2024
Q1 | $2.53M | Sell |
13,902
-97
| -0.7% | -$16.7K | 1.07% | 22 |
|
|
2023
Q4 | $2.17M | Sell |
13,999
-6
| -0% | -$875 | 1.02% | 22 |
|
|
2023
Q3 | $2.09M | Buy |
14,005
+192
| +1% | +$28.2K | 1.09% | 22 |
|
|
2023
Q2 | $1.86M | Buy |
13,813
+66
| +0.5% | +$9.68K | 0.95% | 24 |
|
|
2023
Q1 | $2.19M | Sell |
13,747
-134
| -1% | -$20.5K | 1.14% | 18 |
|
|
2022
Q4 | $2.24M | Sell |
13,881
-96
| -0.7% | -$14.7K | 1.17% | 18 |
|
|
2022
Q3 | $1.88M | Buy |
13,977
+25
| +0.2% | +$3.59K | 1.05% | 20 |
|
|
2022
Q2 | $2.14M | Sell |
13,952
-2,205
| -14% | -$337K | 1.11% | 20 |
|
|
2022
Q1 | $2.62M | Buy |
16,157
+796
| +5% | +$116K | 1.13% | 21 |
|
|
2021
Q4 | $2.08M | Buy |
15,361
+302
| +2% | +$35.7K | 0.84% | 30 |
|
|
2021
Q3 | $1.62M | Buy |
15,059
+102
| +0.7% | +$11.7K | 0.71% | 39 |
|
|
2021
Q2 | $1.69M | Sell |
14,957
-100
| -0.7% | -$11.3K | 0.76% | 35 |
|
|
2021
Q1 | $1.63M | Buy |
15,057
+838
| +6% | +$89.6K | 0.8% | 33 |
|
|
2020
Q4 | $1.52M | Buy |
14,219
+3,941
| +38% | +$379K | 0.82% | 32 |
|
|
2020
Q3 | $900K | Buy |
10,278
+40
| +0.4% | +$3.77K | 0.55% | 49 |
|
|
2020
Q2 | $1M | Buy |
10,238
+1,174
| +13% | +$103K | 0.67% | 41 |
|
|
2020
Q1 | $691K | Buy |
9,064
+652
| +8% | +$55.5K | 0.53% | 47 |
|
|
2019
Q4 | $745K | Buy |
8,412
+5,770
| +218% | +$479K | 0.49% | 44 |
|
|
2019
Q3 | $200K | Buy |
+2,642
| New | +$181K | 0.18% | 63 |
|
|
2017
Q1 | – | Sell |
-9,855
| Closed | -$617K | – | 72 |
|
|
2016
Q4 | $617K | Buy |
9,855
+3,200
| +48% | +$195K | 0.56% | 38 |
|
|
2016
Q3 | $420K | Sell |
6,655
-75
| -1% | -$4.86K | 0.4% | 41 |
|
|
2016
Q2 | $417K | Sell |
6,730
-75
| -1% | -$4.57K | 0.36% | 42 |
|
|
2016
Q1 | $389K | Hold |
6,805
| – | – | 0.35% | 42 |
|
|
2015
Q4 | $403K | Sell |
6,805
-410
| -6% | -$23.6K | 0.37% | 39 |
|
|
2015
Q3 | $393K | Hold |
7,215
| – | – | 0.39% | 39 |
|
|
2015
Q2 | $485K | Buy |
7,215
+240
| +3% | +$15.7K | 0.45% | 36 |
|
|
2015
Q1 | $408K | Sell |
6,975
-535
| -7% | -$32.3K | 0.39% | 38 |
|
|
2014
Q4 | $491K | Sell |
7,510
-5,470
| -42% | -$345K | 0.49% | 35 |
|
|
2014
Q3 | $750K | Hold |
12,980
| – | – | 0.77% | 28 |
|
|
2014
Q2 | $733K | Sell |
12,980
-150
| -1% | -$7.87K | 0.77% | 30 |
|
|
2014
Q1 | $675K | Sell |
13,130
-745
| -5% | -$37.7K | 0.74% | 29 |
|
|
2013
Q4 | $733K | Sell |
13,875
-6,125
| -31% | -$301K | 0.8% | 27 |
|
|
2013
Q3 | $895K | Sell |
20,000
-225
| -1% | -$9.97K | 1.05% | 24 |
|
|
2013
Q2 | $836K | Buy |
+20,225
| New | +$885K | 1.04% | 24 |
|
Other funds holding ABBV
VCM
VPM
Excalibur Management's ABBV Position: Q1 2026 in Review
Excalibur Management increased its AbbVie (ABBV) stake by 0.22% in Q1 2026, buying an estimated $6.66K and bringing the position to 13,479 shares worth $2.93M. The position accounts for 1.05% of the portfolio, ranked #25.
Excalibur Management first reported a position in ABBV in Q2 2013 and has held it in 42 quarters since. The position peaked at $3.18M in Q3 2025. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Excalibur Management held 13,479 shares of AbbVie worth $2.93M as of Q1 2026.
- Excalibur Management bought 30 AbbVie shares in Q1 2026, an estimated $6.66K.
- AbbVie made up 1.05% of Excalibur Management's portfolio in Q1 2026, its #25 holding.
- Excalibur Management first reported a position in AbbVie in Q2 2013 and has held it in 42 quarters since.
- Excalibur Management's AbbVie position peaked at $3.18M in Q3 2025.
- 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Excalibur Management's 13F filing for Q1 2026, filed 5 May 2026.